Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus rhamnosus R0011

Also known as: Lacticaseibacillus rhamnosus R0011, Lactobacillus rhamnosus R0011, L. rhamnosus R0011

Overview

Lacticaseibacillus rhamnosus R0011, formerly known as Lactobacillus rhamnosus R0011, is a probiotic strain belonging to the Lacticaseibacillus genus. It is naturally found in the human gut microbiota and fermented dairy products. This strain is primarily used as a dietary supplement to support gut health, prevent or treat diarrhea, and as an adjuvant in Helicobacter pylori eradication therapy. Research on the L. rhamnosus species is extensive, although specific data on the R0011 strain is less abundant compared to the well-studied L. rhamnosus GG strain. Evidence quality varies, with systematic reviews and meta-analyses often focusing on L. rhamnosus GG. However, recent randomized controlled trials (RCTs) and meta-analyses include R0011 in multi-strain formulations or as a standalone probiotic, demonstrating its efficacy in various clinical settings.

Benefits

Lacticaseibacillus rhamnosus R0011 has demonstrated efficacy in reducing the duration and severity of acute diarrhea, including antibiotic-associated diarrhea (AAD) in both children and adults. Meta-analyses indicate a statistically significant decrease in diarrhea duration, often by approximately one day or more. It also improves Helicobacter pylori eradication rates when used as an adjunct to standard triple therapy, increasing eradication success and reducing side effects such as antibiotic-associated gastrointestinal symptoms. Secondary benefits include potential modulation of gut microbiota composition and immune response, though further study is needed. These benefits are particularly relevant for children and adults with acute infectious diarrhea or AAD, and for patients undergoing H. pylori eradication therapy, especially in regions with high antibiotic resistance.

How it works

Lacticaseibacillus rhamnosus R0011 primarily functions through competitive exclusion of pathogenic bacteria in the gut, enhancing mucosal barrier function, and modulating host immune responses, including anti-inflammatory effects. It also produces antimicrobial substances such as lactic acid and bacteriocins. The probiotic interacts with the gastrointestinal tract microbiota and epithelial cells to restore microbial balance disrupted by infection or antibiotics. It acts locally in the gut, and its survival through gastric acidity and bile is crucial for its efficacy.

Side effects

Lacticaseibacillus rhamnosus R0011 is generally considered safe, with a long history of use in probiotic formulations. Common side effects, occurring in more than 5% of users, include mild gastrointestinal symptoms such as bloating or gas, which are typically transient. Uncommon side effects, affecting 1-5% of users, include rare reports of allergic reactions. Very rare cases of bacteremia or sepsis have been reported in immunocompromised individuals, but there are no significant safety concerns in healthy populations. No major drug interactions have been reported. Contraindications include severe immunosuppression or critical illness, where probiotic use should be carefully considered.

Dosage

Effective doses of Lacticaseibacillus rhamnosus R0011 in clinical trials typically range from 10^8 to 10^10 colony-forming units (CFU) per day. The optimal dosage depends on the specific indication; for diarrhea treatment or prevention, doses around 10^9 CFU daily are commonly used. It is best administered during antibiotic therapy or acute illness for optimal effect. Formulations often combine it with other probiotic strains, although single-strain R0011 supplements are also available. Survival through stomach acid is critical, and enteric-coated capsules or dairy matrices can improve viability. Concurrent prebiotic intake may enhance colonization.

FAQs

Is L. rhamnosus R0011 safe for children?

Yes, L. rhamnosus R0011 has been used safely in pediatric populations for diarrhea management.

Can it be used alongside antibiotics?

Yes, it is often used to prevent or reduce antibiotic-associated diarrhea.

How soon will benefits appear?

Typically, benefits appear within a few days of starting supplementation.

Is it better alone or in combination?

Both single and multi-strain formulations show benefits; combination may enhance efficacy in some cases.

Does it permanently colonize the gut?

Colonization is usually transient; benefits come from continuous or repeated use during risk periods.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/31025399/ – This systematic review and meta-analysis on Lactobacillus rhamnosus GG showed a significant reduction in diarrhea duration and hospitalization rates, with stronger effects observed in European populations. The study included over 1000 participants across multiple studies and found statistically significant results (p < 0.05), supporting the efficacy of the species in managing diarrhea.
https://pubmed.ncbi.nlm.nih.gov/26365389/ – This meta-analysis focusing on L. rhamnosus GG demonstrated its effectiveness in preventing antibiotic-associated diarrhea in children and adults. The study involved over 500 participants per group and reported statistically significant results. These findings provide a benchmark for probiotic efficacy within the species, highlighting its potential in preventing AAD.
https://www.mdpi.com/2072-6643/11/11/2762 – This study investigates the impact of probiotics on Helicobacter pylori eradication therapy. It provides insights into how probiotics, including L. rhamnosus strains, can improve eradication rates and reduce side effects associated with antibiotic treatment, contributing to a better understanding of probiotic-antibiotic interactions.
https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2023.1245993/full – This double-blind RCT evaluated L. rhamnosus R0011 (with L. helveticus R0052) as adjunct therapy for H. pylori eradication and showed improved eradication rates and reduced side effects compared to placebo. The study included at least 60 participants per group and reported statistically significant results (p < 0.05). This is direct evidence supporting R0011’s clinical use in improving H. pylori treatment outcomes.
https://tp.amegroups.org/article/view/85375/html – This article discusses the role of probiotics in preventing and treating various gastrointestinal disorders. It highlights the mechanisms of action and clinical evidence supporting the use of specific probiotic strains, including L. rhamnosus, in managing conditions such as diarrhea and inflammatory bowel disease.